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Objective: Considering the osteoarthritis (OA) model that integrates the biological, 27 
mechanical, and structural components of the disease, the present study aimed to 28 
investigate the association between urinary C-Telopeptide fragments of type II collagen 29 
(uCTX-II), knee joint moments, pain, and physical function in individuals with medial 30 
knee OA. Methods: Twenty-five subjects radiographically diagnosed with knee OA were 31 
recruited. Participants were evaluated through three-dimensional gait analysis, uCTX-II 32 
level, the WOMAC pain and physical function scores, and the 40m walk test. The 33 
association between these variables was investigated using Pearson´s product-moment 34 
correlation, followed by a hierarchical linear regression, controlled by OA severity and 35 
body mass index (BMI). Results: No relationship was found between uCTX-II level and 36 
knee moments. A significant correlation between uCTX-II level and pain, physical 37 
function, and the 40m walk test was found. The hierarchical linear regression controlling 38 
for OA severity and BMI showed that uCTX-II level explained 9% of the WOMAC pain 39 
score, 27% of the WOMAC physical function score, and 7% of the 40m walk test. 40 
Conclusion: Greater uCTX-II level is associated with higher pain and reduced physical 41 
function and 40m walk test performance in individuals with medial knee OA.  42 
Keywords: physical therapy; gait; biomarkers; walk test; disability evaluation. 43 
 44 
Highlights 45 
 There is no association between uCTX-II and the knee joint load; 46 
 The uCTX-II level is associated with pain and physical function; 47 




Knee osteoarthritis (OA) is one of the most prevalent diseases in the world 1, 50 
characterized by the degradation of articular cartilage. Cartilage degradation is a 51 
consequence of the loss of the normal balance between the synthesis and degradation 52 
activity of the chondrocytes 2. The degradation is considered to be a result of mechanical 53 
and biological alterations 3-5. For this reason, studies have investigated how these changes 54 
relate to OA symptoms and whether they can predict knee OA onset and progression 6-8. 55 
The unbalanced activity of the chondrocytes and consequent breakdown of 56 
articular cartilage can be caused by abnormal or excessive loading in the joint 9-11. Knee 57 
adduction moment (KAM) has been used to measure the distribution of load between 58 
medial and lateral compartments of the knee 12-15, more specifically excessive medial 59 
compartment loading as this is the most commonly affected compartment 9. KAM has 60 
been associated with pain 16,17, OA severity 5,18, and progression of the disease 8,19. Knee 61 
adduction angular impulse (KAAI), which is the time integral of the KAM curve during 62 
stance, has also been used to measure knee load through a combination of the duration 63 
and amplitude of KAM 18. KAAI is also associated with the presence 7, severity 18, pain, 64 
and disability 20 in knee OA. More recently, knee flexion moment (KFM) was proposed 65 
to improve the measurement of knee load 21, being associated with cartilage thickness in 66 
the early stages of the disease 22. A longitudinal study demonstrated that higher baseline 67 
KAM and KFM in individuals with medial knee OA were shown to be associated with 68 
reduced knee cartilage thickness at the five-year follow-up 4. Hence, knee moment 69 
variables (KAM, KAAI, and KFM) may be considered appropriate measures of knee joint 70 
load. 71 
Some authors consider mechanical alterations responsible for the occurrence of 72 
biological alterations, and consequent degradation of articular cartilage, in most cases of 73 
knee OA 5,10,11. The biological alterations of articular cartilage can be identified by 74 
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biochemical markers, also called biomarkers 23. Urinary C-tylopeptide type II collagen 75 
(uCTX-II) has been presented as one of the most important OA biomarkers to detect 76 
changes in cartilage 23. The uCTX-II level from a urine sample can measure the systemic 77 
concentration of type II collagen, which is the most abundant protein of the cartilage 78 
matrix 24,25. According to BIPED (Burden of disease, Investigative, Prognostic, Efficacy 79 
of Intervention and Diagnostic) criteria 26, uCTX-II has the ability to diagnose, predict 80 
the progression, and identify the severity of the disease 2,27-30, demonstrating also the 81 
ability to identify healthy individuals at high risk of developing knee OA30,31.  82 
Therefore, both biological and mechanical alterations have been shown to be 83 
related to the onset or progression of knee OA, however, no clear association has been 84 
shown between these components in the current literature. To our knowledge, only one 85 
study has investigated the relationship between uCTX-II and knee loads 32, with the 86 
authors finding an association between uCTX-II level and KAM and KAAI during 87 
walking. However, this association became non-significant after adjusting for disease 88 
severity and walking speed. In addition, they did not investigate the association of uCTX-89 
II with KFM nor with pain and physical function. As KFM has been shown to be 90 
associated with cartilage thickness in the early stages of the disease22, its addition could 91 
improve the understanding of the potential relationship between uCTX-II and knee joint 92 
load.  93 
Only a few studies have explored the relationship between biomarkers 33 and knee 94 
load 34, with pain and physical function. As OA is a persistent condition, current 95 
treatments target pain and physical function improvement/maintenance 3,7,19,35,36. 96 
Exploring how mechanical and biological alterations influence these parameters can 97 
bring new perspectives for pain and disability control and treatment strategies. 98 
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Therefore, the aim of this study was to investigate the association between uCTX-99 
II, knee joint moments (KAM, KFM, and KAAI), pain, and physical function in 100 
individuals with medial knee OA. We hypothesized that uCTX-II level is associated with 101 
pain, physical function, and knee joint moments (KAM, KFM, and KAAI). 102 
Material and Methods 103 
Design 104 
A cross-sectional design was used. 105 
Sample size 106 
A priori sample size calculation was performed by using G* Power 3.1. The calculation 107 
aimed to reach a statistical significance level of 0.05, power of 80%, and a medium effect 108 
size (d = 0.5), considering a correlation test and one tail. Based on these parameters, our 109 
sample size calculation estimated the need for at least 21 subjects. 110 
Subjects 111 
Community-based volunteers were recruited through advertisements in local newspapers, 112 
university websites, and social media. All volunteers underwent anteroposterior 113 
semiflexed weight-bearing, lateral view, and skyline view radiographs and were then 114 
classified according to the Kellgren and Lawrence (KL) criteria 37. As the medial knee 115 
compartment is the most commonly affected 38, only individuals with predominantly 116 
medial knee OA and medial knee pain were included. Therefore, potential participants 117 
were excluded if they presented KL grades in the lateral or patellofemoral compartment 118 
greater than the medial compartment 39. In addition, potential participants were excluded 119 
for any of the following criteria: body mass index (BMI) greater than 35kg/m2 to reduce 120 
soft tissue artifact of marker movement during quantitative gait analysis, unable to walk 121 
unaided for at least 10 minutes, history of hip or knee arthroplasty or osteotomy, had 122 
undergone knee surgery or other nonpharmacological treatment in the 6 months prior to 123 
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the study 40. For participants with bilateral knee OA, the most symptomatic knee was 124 
evaluated. All participants provided written informed consent and the present study was 125 
approved by the Ethics committee for Human Investigations at the Universidade Federal 126 
de São Carlos (UFSCar), São Carlos, SP, Brazil (CAAE: 41716015.0.0000.5504).  127 
Variables 128 
The dependent variable was uCTX-II level, while independent variables were pain, 129 
physical function, and variables obtained from three-dimensional gait analysis. 130 
Dependent variable 131 
The uCTX-II level was measured using fasting urine collected in the early morning 132 
(within 2 hours of waking), second void, and all samples were stored frozen at -80°C until 133 
analysis. The uCTX-II level was determined using an enzyme linked immunosorbent 134 
assay (ELISA) based on a monoclonal antibody raised against a linear six amino acid 135 
epitope of human type II collagen C telopeptide (Urine CartiLaps®ELISA)24. The uCTX-136 
II level was corrected with creatinine concentration (mmol/L) in the sample using an 137 
enzymatic colorimetric routine method41. For this correction we used the formula: 138 
corrected CTX-II Value = 1000xUrine CartiLaps (µg/L)/Creatinine (mmol/L)42. The 139 
intra- and inter-assay coefficients of variation are ≤7.8% and ≤12.2%, respectively42. All 140 
analyses were conducted in duplicate and blinded. 141 
Independent variables 142 
Self-reported pain and physical function were measured using The Western Ontario and 143 
McMaster Universities Osteoarthritis Index (WOMAC). The WOMAC index is a 144 
disease-specific, tri-dimensional, self-administered questionnaire used to assess health 145 
status and health outcomes in individuals with knee OA. The WOMAC contains 24 146 
questions and consists of three subscales: pain, stiffness, and physical function with five, 147 
two, and seventeen questions, respectively. Answers for each of the 24 questions are 148 
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scored on a five-point Likert scales (none=0, slight=1, moderate=2, severe=3, extreme=4) 149 
with total scores ranging from 0 to 96. Higher scores indicate worse disease severity. The 150 
WOMAC questionnaire is well recognized for its adequate validity, reliability, and 151 
responsiveness for individuals with knee OA 43. We used the Portuguese version of the 152 
WOMAC44. 153 
Objective physical function was measured using the 40m walk test. The 40m walk test 154 
was developed to evaluate the ability to walk quickly over short distances, which is an 155 
important activity for a good quality of life. This activity is usually limited in individuals 156 
with knee OA45. Two marks on the ground were placed 10m apart and a cone was placed 157 
2 meters beyond each end of the 10m walkway. Participants, wearing comfortable clothes 158 
and shoes, were instructed to walk as fast as possible, without running, along the walkway 159 
between the two cones, turn around the cone at the end, return, and repeat for a total of 160 
40 m. Participants were timed for this test and based on this time, we calculated the speed 161 
as suggested by previous studies 45-47. A previous study48 found that intra-class correlation 162 
coefficient for inter-rater reliability was 0.96 (95% CI 0.93 – 0.98) and standard error of 163 
measurement was 0.06 (95% CI 0.05 – 0.08). The same study48 found that intra-rater 164 
reliability was 0.92 (95% CI 0.82 – 0.96) and the SEM was 0.07 (95% CI 0.06 – 0.09).   165 
Three-dimensional gait analysis was performed to measure the KAAI and peak KAM and 166 
KFM. Gait was evaluated using an eight-camera Qualisys Oqus 300 motion analysis 167 
system (Qualisys, Gothenburg, Sweden) and a force plate (Bertec Corporation, OH, USA) 168 
to record kinematic and kinetic data at sampling frequencies of 120 and 1200 Hz, 169 
respectively. Participants walked barefoot at a self-selected speed along an 8 m walkway. 170 
For each subject, a static calibration trial followed by five successful trials were collected 171 
for kinetic and kinematic analysis. The following reflective markers were located on 172 
anatomical landmarks bilaterally 49,50: sternal notch, spinous process of C7, acromion, 173 
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iliac crests, anterior and posterior superior iliac spines, greater trochanters of the femur, 174 
medial and lateral femoral epicondyles, medial and lateral malleoli, first, second and fifth 175 
metatarsal heads, base of the fifth metatarsal, and calcaneus. Four clusters built with 4 176 
noncollinear markers were placed over the lateral side of thighs and shanks. Two 177 
additional clusters built with 3 noncollinear markers were positioned on the spinous 178 
process of T4 and T12. Markers on the medial and lateral malleoli, femoral epicondyles, 179 
C7, greater trochanters, and acromion were removed after the static standing calibration 180 
trial was performed. These markers were used to construct the anatomical coordinate 181 
system for the trunk, pelvis, thigh, shank, and foot segments.  182 
The ankle and knee joint centers were calculated as midpoints between the 183 
malleoli and femoral epicondyles, respectively 51. The hip joint center was measured 184 
using the regression model based on the anterior and posterior superior iliac spine markers 185 
52. The pelvic coordinate system was built from markers on the anterior and posterior 186 
superior iliac spines and then contralateral pelvic drop was measured using a laboratory 187 
coordinate system as the reference. The trunk coordinate system was built from markers 188 
on the acromion and iliac crest (bilaterally) and the ipsilateral trunk lean was measured 189 
using a laboratory coordinate system as the reference. For hip, knee and ankle kinematics 190 
we used pelvis, thigh, and shank as local coordinate system respectively. The angular 191 
motion of all assessed joints was defined using Cardan angles in accordance with the 192 
recommendations of the International Society of Biomechanics 53,54. 193 
The kinetic and kinematic data were processed using Qualisys Track Manager 194 
(Qualisys AB) and Visual3D software (C-motion Inc., Rockville, MD, USA). The kinetic 195 
and kinematic data were filtered using a fourth-order, zero-lag, low-pass Butterworth 196 
filter at cut-off frequencies of 6 and 25 Hz, respectively. Smoothing parameters were set 197 
by residual analysis and visual inspection of the processed kinematic and kinetic data. 198 
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The stance phase was determined using a force plate, where the initial contact (IC) and 199 
toe-off (TO) were identified based on a force threshold of 20N55. The kinetic and 200 
kinematic data were normalized to 101 points. KFM, KAM, and KAAI were calculated 201 
using three-dimensional inverse dynamics56,57. KFM and KAM were normalized by the 202 
body mass and height (%Bw*Ht), while KAAI was normalized by the body mass, height, 203 
and time (%Bw*Ht*s). The peak of each variable throughout the stance phase was used 204 
for analysis. 205 
Statistical Analyses 206 
All statistical analyses were performed using SPSS software (Version 20, SPSS Inc., 207 
Chicago, IL, USA). The normality of distribution of all variables was analyzed using the 208 
Shapiro-Wilk test. As the data presented a normal distribution a Pearson’s product-209 
moment correlation coefficient were used to examine the relationship between uCTX-II 210 
level, knee moments, symptoms, and physical function. For all significant correlations 211 
(uCTX-II with pain, physical function, and the 40m walk test) we processed a hierarchical 212 
linear regression.  Based on previous studies, we controlled our analysis for OA severity 213 
(mild or moderate according to the KL score) 25,58 and BMI (kg/m²)59, using these 214 
variables as the first step of the hierarchical linear regression. The second step uCTX-II 215 
levels was added to the model, which means that all changes in the results of regression 216 
analysis (R, R², ∆R², and p-value), from the first step to the second step, were due to 217 
uCTX-II levels inclusion. An alpha level of 0.05 was set for all statistical tests. 218 
Results 219 
A total of 40 potential participants presenting with knee pain were evaluated, 220 
however, 15 were excluded: two had a positive test for an anterior cruciate ligament 221 
injury, two had significant low back pain (more pain in their back than knee), two 222 
presented with hip pain, and the other nine presented with other knee compartments as or 223 
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more affected than the medial knee compartment (7 for the patellofemoral joint and 2 for 224 
the lateral knee compartment). Twenty-five subjects with knee OA were eligible for the 225 
study. For diagnosis, we considered the clinical, radiographic, and history criteria of the 226 
American College of Rheumatology 60. Group characteristics and descriptive values are 227 
presented in table 1. A significant correlation between uCTX-II level and pain, physical 228 
function, 40m walk test, and gait speed was found (Table 2 and Figure 1) while no 229 
significant correlation was found with the other measures. 230 
“INSERT TABLE 1 NEAR HERE” 231 
“INSERT TABLE 2 NEAR HERE” 232 
“INSERT FIGURE 1 NEAR HERE” 233 
After controlling for severity and BMI through a hierarchical linear regression we 234 
found that severity and BMI explained 35% of the variance of the WOMAC pain score, 235 
while uCTX-II level explained an additional 9% of this variance (Table 3). In addition, 236 
severity and BMI explained 39% of the variance in the 40m walk test, while uCTX-II 237 
level explained an additional 7% of this variance (Table 3). Finally, uCTX-II level 238 
explained 27% of the variance in the WOMAC Physical Function Score (Table 3). 239 
“INSERT TABLE 3 NEAR HERE” 240 
Discussion  241 
This cross-sectional study provides evidence that uCTX-II level is positively 242 
associated with pain (r=0.49) and physical function (r=0.53), but negatively associated 243 
with the 40m walk test (r=-0.48), even after controlling for OA severity and BMI.  244 
One objective of this study was to investigate the association between uCTX-II 245 
level and knee joint moments. Although these variables are related to the onset and 246 
progression of the disease, our study could not confirm this association. An earlier study32 247 
has reported an association of uCTX-II level with KAM and KAAI, however, when 248 
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disease severity and walking speed were controlled for in the analysis the association was 249 
no longer significant. The present study investigated this relationship not only using the 250 
KAM and KAAI, but also KFM as an important measure to improve the ability to measure 251 
the medial knee load 21. There are possible reasons why we did not find an association 252 
between uCTX-II and knee joint moments. First, although we used three parameters of 253 
medial knee load (KAM, KFM, and KAAI), they do not represent the total knee load. 254 
However, as we included subjects with predominantly medial KOA as it is the most 255 
commonly affected compartment, the medial knee load was the focus of our analysis. 256 
Second, we measured the fasting level of uCTX-II through a sample of the second void 257 
of morning urine, which means that our volunteers had limited physical effort in the hours 258 
prior to the sample collection. This may have influenced our findings given that the 259 
biomarker response to a mechanical stimulus has been shown to be more sensitive to 260 
understand the relationship between cartilage metabolism and knee load than only resting 261 
levels 61,62. For this reason, future studies should explore the stimulus-response approach 262 
to better understand the relationship between uCTX-II level and knee joint load. Third, 263 
although uCTX-II has been used to analyze individuals with knee OA, perhaps uCTX-II 264 
level was not sensitive enough to correlate with medial knee load measures because of its 265 
systemic characteristics. For this reason, future studies may consider using synovial fluid 266 
from the knee to investigate this relationship, as it would provide responses specifically 267 
from the cartilage of the knee.  268 
The present study showed that uCTX-II level explained part of the variance in 269 
WOMAC pain score (9%), WOMAC physical function score (27%), and the 40m walk 270 
test (7%). In addition, the influence of BMI and disease severity were controlled as both 271 
measures explained 35% of the WOMAC pain score and 39% of the variance in the 40m 272 
walk test. In contrast to these findings, Garnero et al.33 found no correlation of uCTX-II 273 
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levels with the WOMAC total score or subscales (pain, stiffness, and physical function). 274 
However, Garnero’s et al.33 study did not control the influence of BMI and disease 275 
severity which may have influenced their results. 276 
Taking into account that uCTX-II levels represent cartilage destruction, and 277 
considering that this is one of the factors influencing knee pain in individuals with knee 278 
OA 63, finding a variation of 9% in WOMAC pain score assigned to the uCTX-II level is 279 
quite reasonable. Although the present study cannot establish a causal relationship 280 
between uCTX-II level and pain, the results are in agreement with previous studies that 281 
have verified that uCTX-II can be used to predict knee pain in patients with knee OA 2,27. 282 
In the same way, uCTX-II predicted 27% of the variance in WOMAC physical function 283 
score and 7% in the 40m walk test, suggesting that the higher the level of uCTX-II, the 284 
worse the self-reported physical function and the worse physical performance during a 285 
fast walk. Considering that decreased physical function is related to pain 64-66, and also 286 
increased uCTX-II level is related to increased pain, a reduction in physical function, as 287 
uCTX-II level increases, could justify the presence of knee pain. However, as we did not 288 
measure pain during 40m walk test, it is not possible to use knee pain to explain our 289 
results. Further investigation is necessary to clarify the mechanism of the influence of 290 
uCTX-II on pain and physical function in individuals with medial knee OA. Moreover, 291 
longitudinal studies would clarify the causal relationship between uCTX-II, pain, and 292 
physical function.  293 
The present study has several limitations. We did not control for the menstrual 294 
cycle of our female participants, and postmenopausal women usually present high levels 295 
of uCTX-II 25. However, as we used a correlation and regression analyses, subjects were 296 
analyzed using their own data. We also did not evaluate the level of physical activity 2, 297 
although it may have some influence in our findings, our subjects had limited physical 298 
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effort before the collection as urine samples were collected in the morning. In addition, 299 
considering that distinct levels of physical activity can result in different level of knee 300 
pain67, we think that this information should be considered in future studies. The small 301 
sample size in this study may have reduced statistical power and the ability to make 302 
conclusions. Even with a small sample size, it was possible to find some statistically 303 
significant results and to provide new information regarding the relationship between 304 
cartilage metabolism and mechanical joint load. We also think that not measuring pain 305 
during 40m walk test and during the kinematic/kinetic gait assessment is a limitation, as 306 
we understand that this information would help to discuss our findings and also would 307 
help to explain participants’ performance in this functional test. We only included 308 
subjects with a BMI <35kg/m² to reduce skin movement artifacts during gait analysis. 309 
Nonetheless, given that many people with knee OA are overweight or obese, these results 310 
can be partially generalized to individuals with knee OA. In the same way, as we included 311 
only subjects with predominantly medial knee OA, although it is the most affected 312 
compartment of the knee, our findings cannot be generalized to individuals with lateral 313 
and/or patellofemoral knee OA. Finally, our sample performed barefoot walking for gait 314 
analysis, we may have influenced our results as recent studies have shown reduced peak 315 
ground reaction forces during barefoot walking when compared to shod conditions 68,69.  316 
In conclusion, greater uCTX-II level is associated with higher pain and reduced 317 
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Table 1. Demographic and subject gait characteristics. 538 
 KOA group 
(n=25) 
Female (n, %) 12 (48) 
Age (years) 58.2 ± 4.7 
Height (m) 1.7 ± 0.1 
Mass (kg) 79.5 ± 13.6 
BMI (kg/m2) 28.4 ± 3.9 
WOMAC Score  
Pain (0-20) 8.2 ± 3.8 
Stiffness (0-8) 3.4 ± 1.9 
Physical Function (0-
68) 
24.0 ± 13.5 
Walk test – 40m (m/s) 1.7 ± 0.3 
Severity (KL)  
       Grade 2 (n, %) 15 (60) 
       Grade 3 (n, %) 10 (40) 
Gait speed (m/s) 1.18 ± 0.16 
uCTX-II (ng/mmol 
crea) 
26.6 ± 14.9  
Peak KAM 
(Nm/kg.Ht) 
3.02 ± 0.82 
Peak KFM 
(Nm/kg.Ht) 
2.56 ± 1.48 
KAAI (Nm/kg.s.Ht) 1.19 ± 0.46 
Data are mean ± standard deviation or frequency (proportion).  539 
KOA: knee osteoarthritis, BMI: body mass index, WOMAC: Western Ontario & 540 
McMaster Universities Osteoarthritis Index, KL: Kellgren and Lawrence classification, 541 
uCTX-II: urinary C-Telopeptide fragments of type II collagen, ng: nanogram, mmol: 542 
millimole, crea: creatinine, Nm: newton meter, Ht: height, KAM: knee adduction 543 









Table 2. Pearson correlation coefficient (r) between uCTX-II level, knee moments, 551 
symptoms, gait speed, age, BMI and physical function. 552 
 uCTX-II Level  
r  
p-value 
WOMAC Pain score 0.49 * 0.04 
WOMAC Physical Function 
score 
0.53 * 0.02 
Walk test (40m) -0.48 * 0.04 
Peak KAM (Nm/kg.Ht) -0.04 0.89 
Peak KFM (Nm/kg.Ht) 0.03 0.55 
KAAI (Nm/kg.s.Ht) 0.14 0.90 
Gait speed (m/s) -0.54* 0.03 
Age (years) 0.37 0.10 
BMI (kg/m2) 0.17 0.75 
*Significant correlation (p<0.05). 553 
uCTX-II: urinary C-Telopeptide fragments of type II collagen, WOMAC: Western 554 
Ontario & McMaster Universities Osteoarthritis Index, BMI: body mass index, Nm: 555 
newton meter, Ht: height, KAM: knee adduction moment, KFM: knee flexion moment, 556 









































0.59 0.35* 0.35 0.04 







0.43 0.19 0.19 0.21 
2 uCTX-II 0.67 0.45* 0.27 0.03 




0.62 0.39* 0.39 0.02 
2 uCTX-II 0.68 0.46* 0.07 0.03 
  *Significant difference (p<0.05) 583 
WOMAC: Western Ontario & McMaster Universities Osteoarthritis Index, BMI: body 584 



















Figure 1. Scatterplots illustrating the association between uCTX-II with WOMAC pain 602 
score (a), WOMAC physical function score (b), and 40m walk test (c). 603 
 604 
